Zacks.com on MSN

IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use

Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess (linaclotide), for the treatment of functional constipation (FC) in pediatric ...
Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Prescription Demand: Total LINZESS prescription demand in the fourth quarter of 2023 was 50 million LINZESS capsules, a 10% increase compared to the fourth quarter of 2022, per IQVIA. Total ...
Morningstar

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance – LINZESS® (linaclotide) U.S. net ...

Ironwood (IRWD) Q1 2026 Earnings Call Transcript

U.S. net sales forecast of $1.125 billion to $1.175 billion, Ironwood revenue guidance of $450 million to $475 million, and ...
Business Wire

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS ® Prescription Demand

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance. “We made ...